Carlsmed, Inc. Appoints Jennifer Kamocsay as Chief Legal Officer and Secretary

September 29, 2025

CARLSBAD, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced the appointment of Jenifer Kamocsay as Chief Legal Officer and Secretary, effective immediately. Ms. Kamocsay will serve as legal counsel for the Company and oversee compliance and corporate governance.

Ms. Kamocsay brings more than two decades of corporate legal experience as in-house counsel across life science and technology sectors at Akoya Biosicences, Rubius Therapeutics, Inc. and Progress Software Corporation.

“We are pleased to welcome Jennifer to the Carlsmed leadership team as we strengthen our organization and strategically expand our leadership team following our IPO,” said Mike Cordonnier, Chairman and CEO of Carlsmed. “Her deep expertise in corporate governance, securities law and broader legal strategy will be instrumental as we continue to scale our business and prepare for our cervical commercial launch.”

Prior to Akoya, Ms. Kamocsay served as General Counsel and Corporate Secretary of Rubius Therapeutics, Inc., where she was responsible for overseeing and managing all of the company’s legal affairs. Before Rubius, she served as Associate General Counsel and Assistant Secretary at Progress Software Corporation, where she managed the company’s corporate, securities law, and M&A initiatives. Ms. Kamocsay began her career at Skadden, Arps, Slate, Meagher & Flom LLP, where she provided counsel to public and private company clients in the biotechnology and pharmaceutical industries on M&A, securities law, and corporate governance matters. Ms. Kamocsay holds a B.A. in History from the University of California, Los Angeles and a J.D. from Northeastern University School of Law.

About Carlsmed, Inc.

Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond.

Forward Looking Statement

Any statements in this press release about future expectations, plans and prospects, including statements about the Carlsmed’s ability to scale the impact of its aprevo technology platform and advance its personalized spine surgery platform to transform patient outcomes and drive long-term growth, Carlsmed’s current expectation of launching aprevo cervical in the United States in 2026, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including such important factors as are set forth under the caption “Risk Factors” in the Carlsmed’s Registration Statement on Form S-1 on file with the U.S. Securities and Exchange Commission. The forward-looking statements included in this press release represent Carlsmed’s views as of the date of this press release. Carlsmed anticipates that subsequent events and developments will cause its views to change. However, while Carlsmed may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Carlsmed’s views as of any date subsequent to the date of this press release.

Investor Relations
Caroline Corner, PhD
IR@Carlsmed.com

Media
LeAnn Burton
Senior Director Brand Marketing
LBurton@Carlsmed.com